Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene

Journal of Neuroscience

Volumn 22, Issue 22, 2002, Pages 10046-10052

  Bilkei Gorzo, Andras ^a   Racz, Ildiko ^a   Michel, Kerstin ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Anxiety; Depression; Knock out; Mice; Stress; Tachykinin

Indexed keywords

ALCOHOL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; NEUROKININ A; NEUROPEPTIDE; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TACHYKININ; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; GENE DELETION; GENE MUTATION; KNOCKOUT MOUSE; MAZE TEST; MENTAL DISEASE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SOCIAL BEHAVIOR; STRESS; TAC1 GENE;

EID: 0037111842     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-22-10046.2002     Document Type: Article

References (51)

1. 11C]labeled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey. Neuropharmacology 39:664-670.
2. Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 94:147-160.
3. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI (1998) Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392:390-394.
4. Cases O, Self I, Grimsby J, Gaspar P, Chen K, Pournin S, Muller U, Aguet M, Babinet C, Shih JC (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 268:1763-1766.
5. Cheeta S, Tucci S, Sandhu J, Williams AR, Rupniak NM, File SE (2001) Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 915:170-175.
6. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci 23:238-245.
7. de Angelis L, File SE (1979) Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology 64:127-129.
8. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C, Cervero F, Hunt SP (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392:394-397.
9. Emonds-Alt X, Doutremepuich JD, Heaulme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux JP, Proietto V (1993) In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol 250:403-413.
10. File SE (1985) Animal models for predicting clinical efficacy of anxiolytic drugs: Social behaviour. Neuropsychobiology 13:55-62.
11. File SE (1997) Anxiolytic action of a neurokininl receptor antagonist in the social interaction test. Pharmacol Biochem Behav 58:747-752.
12. File SE (2000) NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl) 152:105-109.
13. Fong TM, Yu H, Strader CD (1992) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96, 345 and RP67580. J Biol Chem 267:25668-25671.
14. Gardier AM, Bourin M (2001) Appropriate use of "knockout" mice as models of depression or models of testing the efficacy of antidepressants. Psychopharmacology (Berl) 153:393-394.
15. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P (1996) GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broadspectrum anti-emetic activity. Regul Pept 65:45-53.
16. Griebel G, Perrault G, Soubrie P (2001) Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology (Berl) 158:241-251.
17. Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, Adams JD, Karoum F, Gal J, Shih JC (1997) Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 17:206-210.
18. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R (2002) Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416:396-400.
19. Honkaniemi J, Pelto-Huikko M, Rechardt L, Isola J, Lammi A, Fuxe K, Gustafsson JA, Wikstrom AC, Hokfelt T (1992) Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology 55:451-459.
20. Hurd YL, Keller E, Sotonyi P, Sedvall G (1999) Preprotachykinin-A mRNA expression in the human and monkey brain: An in situ hybridization study. J Comp Neurol 411:56-72.
21. Husum H, Vasquez PA, Mathe AA (2001) Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: Lithium treatment normalizes tachykinins. Neuropsychopharmacology 24:183-191.
22. Jesberger JA, Richardson JS (1988) Brain output dysregulation induced by olfactory bulbectomy: An approximation in the rat of major depressive disorder in humans? Int J Neurosci 38:241-265.
23. Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer A (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535-538.
24. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
25. Leonard BE, Tuite M (1981) Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 22:251-286.
26. Liu X, Gershenfeld HK (2001) Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry 49:575-581.
27. Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315-322.
28. Murtra P, Sheasby AM, Hunt SP, De Felipe C (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405:180-183.
29. Otmakhova NA, Gurevich EV, Katkov YA, Nesterova IV, Bobkova NV (1992) Dissociation of multiple behavioral effects between olfactory bulbectomized C57BL/6J and DBA/2J mice. Physiol Behav 52:441-448.
30. Porsolt RD (1997) Historical perspective on CMS model. Psychopharmacology (Berl) 134:363-364, 371-367.
31. Porsolt RD (2000) Animal models of depression: Utility for transgenic research. Rev Neurosci 11:53-58.
32. Porsolt RD, Bertin A, Jalfre M (1977a) Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336.
33. Porsolt RD, Le Pichon M, Jalfre M (1977b) Depression: A new animal model sensitive to antidepressant treatments. Nature 266:730-732.
34. Ribeiro-da-Silva A, Hokfelt T (2000) Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 34:256-271.
35. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L (1984) Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 19:509-516.
36. Rochford J, Beaulieu S, Rousse I, Glowa JR, Barden N (1997) Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: Effects of diazepam and FG-7142. Psychopharmacology (Berl) 132:145-152.
37. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A (2000) Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413-1421.
38. Rupniak NM, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S, de Felipe C, Hunt SP, Oates B, Wheeldon A (2001) Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497-508.
39. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC (2001) Presence of NK2 binding sites in the rat brain. J Neurochem 79:985-996.
40. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ (2001) Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98:1912-1917.
41. Schramm NL, McDonald MP, Limbird LE (2001) The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 21:4875-4882.
42. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioural and pharmacological characterisation of the elevated "zeromaze" as an animal model of anxiety. Psychopharmacology (Berl) 116:56-64.
43. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K (1996) Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 739:70-78.
44. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrie P (2001) Selective blockade of neurokinin-2 receptors produces antidepressantlike effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299:449-458.
45. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology 85:367-370.
46. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD (1987) The automated tail suspension test: A computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11:659-671.
47. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC (1996) Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7-14.
48. Vaugeois JM, Passera G, Zuccaro F, Costentin J (1997) Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacology (Berl) 134:387-391.
49. Yoshikawa T, Watanabe A, Ishitsuka Y, Nakaya A, Nakatani N (2002) Identification of multiple genetic loci linked to the propensity for "behavioral despair" in mice. Genome Res 12:357-366.
50. Zernig G, Troger J, Saria A (1993) Different behavioral profiles of the non-peptide substance P (NK1) antagonists CP-96, 345 and RP 67580 in Swiss albino mice in the black-and-white box. Neurosci Lett 151:64-66.
51. Zimmer A, Zimmer AM, Baffi J, Usdin T, Reynolds K, Konig M, Palkovits M, Mezey E (1998) Hypoalgesia in mice with a targeted deletion of the tachykinin I gene. Proc Natl Acad Sci USA 95:2630-2635.